Drug Trial Radar · NCT06526377
Vilamakitug in Spondyloarthritis Placebo-controlled Investigation for Efficacy
Last checked: Nov 19, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Sep 2028
Study completion Sep 2028
Sponsor
- Lead sponsor
- XBiotech, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to find out if the study drug will work as a new therapy for axSpA patients. This study is placebo-controlled, and evaluates if study drug can treat symptoms of axSpA, including global disease activity, pain, function and inflammation.
Conditions
- Axial Spondyloarthritis
- Ankylosing Spondylitis
- r-axSpA
- Nr-axSpA
Interventions
vilamakitugDrug
Vilamakitug is a monoclonal antibody preparation, indistinguishable from a natural antibody isolated from a healthy human.
placeboDrug
placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants achieving ASAS40.Time frame: Baseline to week 16
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.